BioSpace News Archive

Primary endpoint was achieved, with dexpramipexole demonstrating a statistically significant reduction in blood eosinophil count over 12 weeks

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today reported preliminary unaudited revenue results for the three months ended December 31, 2020 and introduced revenue guidance expectations for the twelve months ended December 31, 2021. Management Commentary: “We continued to see improvements in the operating environment in our key markets in the fourth quarter as evidenced by

The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Gabrielle Sulzberger as a new member, effective January 25, 2021 . As a member of Lilly’s board, she will serve on both the Audit Committee and the Ethics and Compliance Committee. Ms. Sulzberger is a strategic advisor to Two Sigma Impact, a private equity

The continued progression of Microbot Medical Inc.’s (Nasdaq: MBOT) LIBERTY™ Robotic System was further demonstrated as the Company announced the successful completion of an additional feasibility animal study using the world’s first fully disposable surgical robotic system

Ideal Location for the Developer of High Precision, Image-Guided Laser Ablation System for Prostate Cancer Treatments

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the first patient has been enrolled in its pivotal Phase 3 clinical trial evaluating the safety and efficacy of ReNu®, a cryopreserved amniotic suspension allograft (ASA), for the managem

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company’s HF10® therapy for patients with chronic pain. Results will be presented at the 2021 North Amer

Oragenics, Inc. (NYSE American: OGEN) today issued the following letter to stockholders from its President and Chief Executive Officer, Alan Joslyn, Ph.D.: To My Fellow Stockholders, With so much encouraging news recently around COVID-19 vaccine development, this is an excellent time to update

Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities Topline data from full study population of 350 patients and results of second study of KB109 are expected in the first quarter of 2021

One of the leading contract manufacturing firms in the US, MiQ Partners, has hired Olaf Tessarzyk as Chief Executive Officer to help lead the company through a new era of market expansion and growth.